Molecular Assemblies, Inc.

Join Our Team as a Marketing Associate! Are you passionate about innovative life science technology and eager to drive business growth? We are looking for a dynamic Marketing Associate to help revolutionize the biotech industry with our cutting-edge enzymatic DNA synthesis technology! Apply now and be part of something extraordinary: https://lnkd.in/gs_HSCpY

If you missed it, check out this insightful article featuring our CTO, Phil Paik, on the future of DNA synthesis and its transformative potential in biotech. Discover how our cutting-edge enzymatic DNA synthesis technology is revolutionizing research and opening new frontiers in genetic science.

Discover the future of DNA synthesis with our latest white paper highlighting our Fully Enzymatic Synthesis™ (FES™) technology achieving 99.9% cycle efficiency up to 400nt! ! Learn more: https://lnkd.in/gTdUc27b Dive into how our FES technology surpasses traditional chemical methods in both length and accuracy. Perfect for cutting-edge applications like CRISPR gene editing, molecular cloning and gene assembly. What’s Inside: - Demonstration of FES™ synthesizing long, highly accurate oligonucleotides - Comparison with chemical synthesis limits - Applications in CRISPR, molecular cloning, and gene assembly Unlock the potential of your research.  #DNAuncompromised #enzymaticDNAsynthesis #FES #DNASynthesis #CRISPR #GeneEditing #Biotech #synbio

We’re thrilled to be featured in Genetic Engineering & Biotechnology News as they review the latest next-generation DNA synthesis technologies! The article highlights how our Fully Enzymatic Synthesis technology produces high-quality, long oligos, no matter the sequence complexity. Check it out – you might even recognize a familiar face in the top photo... Phil Paik! #DNAuncompromised #DNA #synthesis #syntheticbiology #lifesciences #synbio #CRISPR #geneediting #precisionmedicine

Welcome Brian LaPutka to the MAI team as Key Account Manager! Brian has 15 years of product and account management experience and is dedicated to accelerating scientific discovery through commercializing life science research products. He joins us as we advance our #FES #DNAsynthesis into early commercial access to power the future of hashtag#synbio applications. Our fully enzymatic process operates at a >99.9% cycle efficiency creating highly pure DNA regardless of length or sequence complexity without the need for post-process purification! If you’re on the West Coast, Brian is available to answer questions on how our fully #enzymaticDNAsynthesis can accelerate research and therapeutic development: https://lnkd.in/gpnmZX_Q #DNAuncompromised #DNA #synthesis #syntheticbiology #lifesciences #synbio #CRISPR #geneediting #precisionmedicine

The field of synthetic biology is at an inflection point – ready to accelerate the creation of personalized and cost-effective genetic medicines. Our CTO Phil Paik explains that at the foundation of this parardigm shift is the ability of new enzymatic DNA synthesis approaches to produce longer chains of DNA with higher accuracy than currently used chemical-based synthesis. Read the full article here: https://lnkd.in/daa84eQA #DNAuncompromised #enzymaticDNAsynthesis #DNAsynthesis #FES #DNA #CRISPR #geneediting #geneticmedicines #genomics #genetics #synbio #SynBioBeta2024

That’s a wrap! Thank you SynBioBeta for another fabulous event with great presentations and people. If you missed us at #SynBioBeta2024, you can contact us here: https://lnkd.in/gSEPefWm #DNAuncompromised #enzymaticDNAsynthesis

We are excited to announce at #SynBioBeta2024 the launch of our partner program for onsite synthesis of long, pure, accurate DNA and the availability of 400mer oligonucleotides for early ordering. We are limiting our 400mer offering to 20 customers. If you’d like to get priority access, contact us here: https://lnkd.in/e46btC7K Read the release for more: https://lnkd.in/g--MagpX #enzymaticDNAsynthesis #DNAsynthesis #DNA #DNAuncompromised #CRISPR #geneediting #synbio

#SynBioBeta2024 starts tomorrow, and we are excited to be mainstage on Day 1 discussing how #enzymaticDNAsynthesis technology is accelerating the future of medicine and other industries. If you are attending the conference, stop by booth #107, see us at one of our talks, or reach out to book time: https://lnkd.in/e46btC7K 🗓️Tuesday, May 7, 9:05am PT, Mainstage Panel: From Complexity to Commercialization: The DNA Synthesis Saga Continues 🗓️Wednesday, May 8, 2:45pm PT, Breakout Session (Room 210B): Fully Enzymatic Synthesis: Unlocking Synthetic Biology's Potential with MAI's CTO Phil Paik and Stacia Wyman, from the Innovative Genomics Institute at UC Berkeley. 🗓️Wednesday, May 8, 5:00pm PT, Mainstage Fireside Chat: Crafting Cures – How Synthetic Biology Personalizes Precision Medicine with MAI's Chair Larry G Stambaugh and SyntheX’s CEO, Maria Soloveychik If you won’t be at SynBioBeta, check out our new product page: https://lnkd.in/gpnmZX_Q.

The ability to synthesize or “write” #DNA is essential to research, especially for biotech, but it’s been limited until now. We are excited to share more at #SynBioBeta24 about the coming #synbio revolution that will be driven by #enzymaticDNAsynthesis. If you are attending the conference, stop by booth #107, see us at one of our talks, or reach out to book time: https://lnkd.in/e46btC7K 🗓️Tuesday, May 7, 9:05am PT, Mainstage Panel: From Complexity to Commercialization: The DNA Synthesis Saga Continues 🗓️Wednesday, May 8, 2:45pm PT, Breakout Session (Room 210B): Fully Enzymatic Synthesis: Unlocking Synthetic Biology's Potential with MAI's CTO Phil Paik 🗓️Wednesday, May 8, 5:00pm PT, Mainstage Fireside Chat: Crafting Cures – How Synthetic Biology Personalizes Precision Medicine with MAI's Larry G Stambaugh #DNAuncompromised #DNAsynthesis #FES #CRISPR #geneediting #geneticmedicines #genomics #genetics #proteinengineering #agbio